Clinical Trials
NeuroSense's ALS Drug PrimeC Shows Promise with 58% Survival Improvement, Pharmaceutical Partnership Imminent
NeuroSense Therapeutics' experimental ALS treatment PrimeC demonstrates significant potential in clinical trials, with the company positioned for a major pharmaceutical partnership and potential breakthrough in neurodegenerative disease treatment.
Soligenix's HyBryte™ Demonstrates Promising Results in Rare Skin Cancer Treatment
A novel skin cancer therapy shows a 75% response rate in treating cutaneous T-cell lymphoma, offering potential hope for patients with limited treatment options. The treatment's safety profile and rapid results could significantly impact rare cancer care.
Kairos Pharma Secures Department of Defense Grant for Lung Cancer Biomarker Research
Kairos Pharma has received a Department of Defense grant to advance research on lung cancer biomarkers, furthering its innovative approach to targeting drug resistance in cancer treatments. The company is progressing clinical trials for its lead candidates ENV105 and KROS101 with promising potential in oncology.
Calidi Biotherapeutics Taps Eric Poma as New CEO to Drive Clinical Growth Strategy
Biotech firm Calidi Biotherapeutics has appointed Eric Poma as its new CEO, signaling a strategic leadership transition aimed at advancing its cancer-targeting stem cell-based virotherapy platform into later-stage clinical development.
Calidi Biotherapeutics to Showcase Innovative Cancer Immunotherapy Platform at Investor Webinar
Calidi Biotherapeutics will host an investor webinar highlighting its stem cell-based delivery platforms for oncolytic virus therapies, featuring updates on promising cancer treatment programs designed to enhance immune system response.
Soligenix Advances COVID-19 Vaccine Candidate CiVax Amid Ongoing Global Health Threat
Soligenix is developing CiVax, a heat-stable COVID-19 vaccine candidate, in response to persistent global health risks from the virus, with recent preclinical studies showing promising protection against multiple variants.
Mayo Clinic Researcher to Present Findings on Aditxt's ADI-100™ Preclinical Study
Aditxt Inc. will host a May 2 update featuring Mayo Clinic's Dr. Charles Howe discussing key findings from a preclinical study of ADI-100™, offering insights into the company's immune modulation therapy research.
Calidi Biotherapeutics Receives FDA Clearance for Innovative Cancer Treatment Trial
Biotech firm Calidi Biotherapeutics has obtained FDA approval to begin clinical trials of CLD-201, a novel stem cell-based virotherapy targeting solid tumors. The therapeutic approach combines adipose-derived stem cells with oncolytic vaccinia virus, potentially offering a breakthrough in treating challenging cancer types.
DoD Awards $876,000 Grant to Advance Lung Cancer Biomarker Research at Cedars-Sinai
The U.S. Department of Defense has provided funding to Cedars-Sinai Medical Center to support biomarker research for Kairos Pharma's experimental lung cancer treatment, focusing on identifying potential early intervention strategies for patients developing resistance to current therapies.
Global Vision Study Launches Using App-Based Eye Exercise Program
A new study using the SniperSight app aims to validate century-old eye exercise techniques as a potential solution for the growing global vision crisis, with projections showing over 4 billion people will need vision correction by 2050.
Neutra Corp Expands into Clinical Research with New Site Management Program
Healthcare company Neutra Corp launches a technology-driven Site Management Organization pilot program to improve clinical trial efficiency and patient outcomes, marking a significant shift in how clinical research sites are managed and supported.
Common Migraine Drug Shows Promise in Reducing Stroke Risk for Women
New research reveals propranolol, a widely-used medication for migraines and high blood pressure, may significantly reduce ischemic stroke risk in women with migraines, particularly those without aura, highlighting an important advancement in women's cardiovascular health management.
High-Intensity Walking Program Shows Promising Results in Early Stroke Recovery
A new study demonstrates that incorporating 30 minutes of progressive walking exercise into standard stroke rehabilitation significantly improves patient mobility and quality of life, potentially reshaping stroke recovery protocols across rehabilitation facilities.